Potential new therapeutic molecular target to fi...(s first discovered the role of sphingosi...)
Navigation Links
Potential new therapeutic molecular target to fight cancer
Date:11/1/2007
s, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. Spiegel and her team are continuing this work to better understand the functions of these enzymes.
'/>"/>
| Contact: Sathya Achia-Abraham sbachia@vcu.edu 804-827-0890 Virginia Commonwealth University Source:Eurekalert |
Related biology news :
1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Simple drug has the potential to save many lives threatened by malaria
5. Potential treatments for neurofibromatosis
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Potential Drug Target For Treating Cocaine Abuse Found
8. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
9. Engineers improve plastics potential for use in implants by linking it to biological material
10. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
11. Improving the potential of cancer vaccines
Post Your Comments:
Breaking Biology News(10 mins): Killer catfish? Venomous species surprisingly common, study finds 2Climate projections underestimate CO2 impact 2University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids 2One Step Closer to New Diabetes Treatment 62123 1Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 1Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 2Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 3Labopharm Enters Into CAD 2425 Million Standby Equity Distribution Agreement 62115 1Labopharm Enters Into CAD 2425 Million Standby Equity Distribution Agreement 62115 2Labopharm Enters Into CAD 2425 Million Standby Equity Distribution Agreement 62115 3
Other Biology News:Coal and black liquor can produce energy from papermaking 2Girls prefer pink, or at least a redder shade of blue 2New 'chemically-sensitive MRI scan' may bypass some invasive diagnostic tests in next decade 2
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
[0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner [0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea[0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |